



COMMISSION OF THE EUROPEAN COMMUNITIES

Brussels, 11.12.1996
COM(96) 563 final

96/0268 (ACC)

Proposal for a

COUNCIL REGULATION (EC)

Providing for duty free treatment for specified pharmaceutical active ingredients bearing an "international nonproprietary name" (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty free treatment as pharmaceutical products from certain INNs whose predominate use is not pharmaceutical.

(presented by the Commission)

EXPLANATORY MEMORANDUM

1. Pursuant to the conclusions reached in Uruguay Round Record of Discussions (L/4740 of 25.3.1994) on duty free treatment for pharmaceutical products, the Commission has participated in the first review of the product coverage to include, by consensus, additional products for duty free treatment.
2. The outcome of the review is that 231 pharmaceutical active ingredients bearing an "international nonproprietary name" (INN) from the World Health Organisation and 234 products used for the manufacture of finished pharmaceuticals should be added to the list of products already receiving duty free treatment and also that the list of specified prefixes and suffixes for salts and esters of INNs should be expanded by 84 names.
3. In addition it was concluded that the situation should be rectified in respect of 25 INNs whose use was predominantly non-pharmaceutical by deleting them from the list of INNs receiving duty free treatment.
4. The Commission proposes in line with other countries granting duty free treatment for these additional products as early as possible in 1997 that the duty free treatment shall commence from 1.1.97.
5. For these reasons the Commission proposes that the Council adopt the Regulation contained in the Annex to this communication.

PROPOSAL FOR A COUNCIL REGULATION (EC)

Providing for duty free treatment for specified pharmaceutical active ingredients bearing an "international nonproprietary name" (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty free treatment as pharmaceutical products from certain INNs whose predominant use is not pharmaceutical

THE COUNCIL OF THE EUROPEAN UNION

Having regard to the Treaty establishing the European Community, and in particular Article 113 thereof,

Having regard to the proposal from the Commission,

Whereas, in the course of the Uruguay Round negotiations the Community and a number of countries discussed duty free treatment of pharmaceutical products;

Whereas the participants in those discussions concluded that in addition to products falling in the Harmonised System (HS) chapter 30 and HS Headings 2936, 2937, 2939 and 2941, duty free treatment should be given to designated pharmaceutical active ingredients bearing an "international nonproprietary name" (INN) from the World Health Organisation as well as specified salts, esters and hydrates of such products, and also to designated products used for the production and manufacture of finished products;

Whereas the results of the discussions, as set out in the Record of Discussions¹, were incorporated into the tariff schedules of the participants annexed to the Marrakesh Protocol to GATT 1994;

Whereas they also concluded that representatives of the WTO members party to the Record of discussions would meet under the auspices of the Council for Trade in Goods of the WTO, normally at least once every three years - to review the product coverage with a view to including, by consensus, additional pharmaceutical products for tariff elimination;

Whereas the first such review has taken place with the conclusion that additional INNs and products used for production and manufacture of finished pharmaceuticals should be granted duty free treatment and that the list of specified prefixes and suffixes for salts and esters of INNs should be expanded;

Whereas in the context of the review it was concluded that it was appropriate to rectify the situation with regard to certain INNs whose use was predominantly non-pharmaceutical and which had been inadvertently included among those INNs already receiving duty free treatment.

¹ GATT Document L/7430

HAS ADOPTED THIS REGULATION:

Article 1

From 1 January 1997 the Community shall also accord duty free treatment for the INNs listed in Annex I as well as the salts, esters and hydrates of such products.

Article 2

From 1 January 1997 the Community shall also accord duty free treatment for the products used in the production and manufacture of pharmaceutical products listed in Annex II.

Article 3

From 1 January 1997 the specified prefixes and suffixes of INNs eligible for duty free treatment shall also include those listed in Annex III.

Article 4

From 1 January 1997 the products listed in Annex IV together with the salts, esters and hydrates of such products shall no longer benefit from duty free treatment.

Article 5

This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Communities.

This Regulation shall be binding in its entirety and directly applicable in all Member states.

Done at Brussels,

For the Council

The President

Annex I

Additional INNs to receive duty free treatment

Annex II

Additional pharmaceutical intermediates, ie compounds used for the manufacture of finished pharmaceutical products, to receive duty free treatment.

Annex III

Additions to the list of prefixes and suffixes which, in combination with the INNs, describe salts, esters or hydrates of INNs.

Annex IV

INNs which shall no longer benefit from duty free treatment

FINANCIAL STATEMENT

Section 1. Financial Implications

1. Proposal for a Council Regulation providing duty free treatment for 465 pharmaceutical products and withdrawing duty free treatment from 25 products whose predominant use is not pharmaceutical.
2. Budget heading: (loss of revenue: not known)
3. Legal basis: Article 113
4. Description

The proposal regulation is a consequence of the agreement reached in the Uruguay Round to undertake a periodic review of the agreement with a view to including, by consensus, additional products for duty free treatment.

5. Type of revenue: Loss of revenue for duties paid on third country imports.
6. Change in level of revenue:

The withdrawal of duty free treatment from products whose use was predominantly non-pharmaceutical with subsequent revenue gains will offset a large proportion of the revenue loss for duty free treatment being granted to other products. No figures are available for the amounts involved but with this element taken into account the duty loss is likely to be less than 2 MECU.

Annex I

Additional INNs to receive duty free treatment

| CN code | CAS RN | Name |
|------------|-------------|--------------------------------|
| 2844 40 30 | 113716-48-6 | iolopride (123 I) |
| | 142481-95-6 | technetium (99m Tc) furifosmin |
| 2846 90 00 | 131069-91-5 | gadoversetamide |
| | 135326-11-3 | gadoxetic acid |
| | 138721-73-0 | sprodiamide |
| 2914 40 90 | 20098-14-0 | idramantone |
| 2916 39 00 | 71109-09-6 | vedaprofen |
| 2918 30 00 | 22161-81-5 | dexketoprofen |
| | 112665-43-7 | seratrodast |
| 2918 90 90 | 139403-31-9 | pimilprost |
| 2921 49 90 | 136236-51-6 | rasagiline |
| 2922 49 70 | 6582-31-6 | dapabutan |
| 2923 90 00 | 1794-75-8 | laurcetium bromide |
| 2924 10 00 | 1675-66-7 | adelmidrol |
| | 62304-98-7 | thymalfasin |
| | 132787-19-0 | tradecamide |
| | 129009-83-2 | versetamide |
| 2924 29 90 | 147362-57-0 | loviride |
| | 94497-51-5 | tamibarotene |
| 2925 19 80 | 144849-63-8 | bisnafide |
| 2925 20 00 | 137159-92-3 | aptiganel |
| 2926 90 80 | 137109-71-8 | balazipone |
| | 147076-36-6 | laflunimus |
| 2928 00 90 | 141579-54-6 | fenleuton |
| 2930 90 16 | 87573-01-1 | salnacedin |
| 2930 90 70 | 90357-06-5 | bicalutamide |
| | 112573-72-5 | dexecadotril |
| | 107023-41-6 | pobilukast |
| | 81110-73-8 | racecadotril |
| 2931 00 50 | 132236-18-1 | zifrosilone |
| 2931 00 80 | 114084-78-5 | ibandronic acid |
| | 124351-85-5 | incadronic acid |
| | 63132-39-8 | olpadronic acid |
| 2932 99 70 | 105674-77-9 | lanprostion |
| 2932 99 90 | 123407-36-3 | arteffene |
| | 132017-01-7 | bervastatin |
| | 110816-79-0 | cromoglicate lisetil |
| | 149494-37-1 | ebalzotan |
| | 151581-24-7 | iralukast |
| | 113806-05-6 | olopatadine |
| | 139110-80-8 | zanamivir |
| 2933 29 90 | 158682-68-9 | elisartan |
| | 116684-92-5 | galdansetron |
| | 89371-44-8 | imidaprilat |
| | 138402-11-6 | irbesartan |
| | 118072-93-8 | zoledronic acid |
| 2933 39 95 | 119257-34-0 | besipirdine |
| | 118248-91-2 | fodipir |
| | 155415-08-0 | inogatran |
| | 121750-57-0 | itameline |
| | 144412-49-7 | lamifiban |
| | 155319-91-8 | mangafodipir |
| | 150443-71-3 | nicanartine |
| | 29876-14-0 | nicotredole |
| | 144035-83-6 | piclamilast |
| | 137795-35-8 | spiroglumide |
| | 147025-53-4 | talsaclidine |
| | 149488-17-5 | troviridine |
| 2933 40 10 | 127294-70-6 | balofloxacin |
| | 143383-65-7 | premafloxacin |
| | 143224-34-4 | telinavir |

| | | |
|------------|-------------|------------------------|
| 2933 40 90 | 96946-42-8 | cisatracurium besilate |
| 2933 40 90 | 158966-92-8 | montelukast |
| | 136668-42-3 | quiflapon |
| 2933 59 70 | 127266-56-2 | adatanserin |
| | 106941-25-7 | adefovir |
| | 113852-37-2 | cidofovir |
| | 150756-35-7 | efletirizine |
| | 119687-33-1 | iganidipine |
| | 127759-89-1 | lobucavir |
| | 140945-32-0 | mapinastine |
| | 134208-17-6 | mazapertine |
| | 96604-21-6 | ocinaplone |
| | 148504-51-2 | ripisartan |
| | 115762-17-9 | ruzadolane |
| | 118420-47-6 | tagorizine |
| | 137234-62-9 | voriconazole |
| | 151319-34-5 | zaleplon |
| 2933 79 00 | 148396-36-5 | fradafiban |
| | 74436-00-3 | geclosporin |
| | 143943-73-1 | lirequinil |
| | 106730-54-5 | olprinone |
| | 135548-15-1 | oxeclosporin |
| | 145733-36-4 | tasosartan |
| | 143343-83-3 | toborinone |
| 2933 90 95 | 137882-98-5 | abitesartan |
| | 114607-46-4 | acitazanolast |
| | 120511-73-1 | anastrozole |
| | 134523-00-5 | atorvastatin |
| | 128270-60-0 | bivalirudin |
| | 139481-59-7 | candesartan |
| | 54278-85-2 | candocuronium iodide |
| | 105806-65-3 | efegatran |
| | 62568-57-4 | emideltide |
| | 120081-14-3 | goralatide |
| | 142880-36-2 | ilomastat |
| | 62732-44-9 | ipidacrine |
| | 116287-14-0 | lanperisone |
| | 112809-51-5 | letrozole |
| | 116644-53-2 | mibefradil |
| | 136122-46-8 | mipitroban |
| | 144702-17-0 | pomisartan |
| | 132036-88-5 | ramosetron |
| | 106308-44-5 | rufinamide |
| | 144701-48-4 | telmisartan |
| | 147059-72-1 | trovafloxacin |
| 2934 10 00 | 149079-51-6 | cartasteine |
| | 128312-51-6 | cinalukast |
| | 51287-57-1 | denotivir |
| | 101001-34-7 | pamicogrel |
| | 136433-51-7 | tazofelone |
| | 138742-43-5 | zankiren |
| 2934 20 90 | 144665-07-6 | lubeluzole |
| | 150915-41-6 | perospirone |
| | 146939-27-7 | ziprasidone |
| 2934 90 60 | 130370-60-4 | batimastat |
| | 133040-01-4 | eprosartan |
| | 135202-79-8 | ilonidap |
| | 114686-12-3 | imitrodast |
| | 132418-36-1 | rocepafant |
| | 132418-35-0 | setipafant |
| 2934 90 70 | 125533-88-2 | mofarotene |
| | 127045-41-4 | pazufloxacin |
| 2934 90 80 | 118292-40-3 | tazarotene |
| 2934 90 98 | 151356-08-0 | afovirsen |

| | | |
|------------|-------------|----------------------|
| | 138298-79-0 | alnespirone |
| | 152317-89-0 | alniditan |
| | 153420-96-3 | atibeprone |
| | 143393-27-5 | azalanstat |
| | 149908-53-2 | azimilide |
| | 150490-85-0 | berupipam |
| | 154361-50-9 | capecitabine |
| | 133099-04-4 | darifenacin |
| | 137500-42-6 | darsidomine |
| | 114030-44-3 | dexpemedolac |
| | 115464-77-2 | elopiprazole |
| | 141790-23-0 | fozivudine tidoxil |
| | 122254-45-9 | glenvastatin |
| | 143443-90-7 | ifetroban |
| | 82857-82-7 | ilepcimide |
| | 104454-71-9 | ipenoxazone |
| | 118288-08-7 | lafutidine |
| | 138068-37-8 | lepirudin |
| | 78994-23-7 | levormeloxifene |
| | 116476-16-5 | levosemotiadil |
| | 148152-63-0 | napitane |
| | 84558-93-0 | netivudine |
| | 147432-77-7 | ontazolast |
| | 139225-22-2 | panamesine |
| | 103255-66-9 | pazinaclone |
| | 123447-62-1 | prulifloxacin |
| | 131986-45-3 | xanomeline |
| | 145781-32-4 | zolasartan |
| 2935 00 90 | 147536-97-8 | bosentan |
| | 136817-59-9 | delavirdine |
| | 119905-05-4 | delequamine |
| | 112966-96-8 | domitroban |
| | 125279-79-0 | ersentilide |
| | 139133-26-9 | lexipafant |
| | 154397-77-0 | napsagatran |
| | 139133-27-0 | nupafant |
| | 116649-85-5 | ramatroban |
| | 133276-80-9 | samixogrel |
| | 146623-69-0 | saprisartan |
| | 149556-49-0 | susalimod |
| | 144494-65-5 | tirofiban |
| | 139308-65-9 | tolafentrine |
| | 107753-78-6 | zafirlukast |
| 2936 29 90 | 131875-08-6 | lexacalcitol |
| 2937 10 10 | 9002-68-0 | follitropin alfa |
| | 152923-57-4 | lutropin alfa |
| 2937 22 00 | 103466-73-5 | icometasone enbutate |
| 2937 29 90 | 144459-70-1 | rofleponide |
| 2937 99 00 | 124478-60-0 | aglepristone |
| | 140703-51-1 | examorelin |
| | 133107-64-9 | insulin lispro |
| | 144743-92-0 | teverelix |
| 2939 50 90 | 151581-23-6 | apaxifylline |
| | 132210-43-6 | cipamfylline |
| | 100324-81-0 | lisofylline |
| | 98833-92-2 | stacofylline |
| 2939 90 90 | 135905-89-4 | mirisetron |
| | 117086-68-7 | ricasetron |
| | 25775-90-0 | zucapsaicin |
| 2940 00 90 | 133692-55-4 | seprilose |
| 2941 90 00 | 127785-64-2 | basifungin |
| 2941 90 00 | 116853-25-9 | cefluprenam |
| | 122841-10-5 | cefoselis |
| | 156131-91-8 | dimadectin |

| | | |
|------------|-------------|--------------------------|
| | 123997-26-2 | eprinomectin |
| | 149951-16-6 | lenapenem |
| | 108852-90-0 | nemorubicin |
| | 159445-62-2 | orientiparcin |
| | 156769-21-0 | sanfetrinem |
| 3001 90 99 | 120993-53-5 | desirudin |
| 3002 10 91 | 143653-53-6 | abciximab |
| | 156227-98-4 | afelimomab |
| | 151763-64-3 | capromab |
| | 152923-56-3 | dacliximab |
| | 145832-33-3 | detumomab |
| | 142864-19-5 | enlimomab |
| | 152981-31-2 | inolimomab |
| | 150631-27-9 | nacolomab tafenatox |
| | 159445-64-4 | odulimomab |
| | 147191-91-1 | priliximab |
| | 153101-26-9 | regavirumab |
| | 148189-70-2 | votumumab |
| 3002 10 95 | 143090-92-0 | anakinra |
| | 143631-61-2 | atexakin alfa |
| | 148637-05-2 | cilmostim |
| | 154725-65-2 | epoetin epsilon |
| | 148363-16-0 | epoetin omega |
| | 102786-52-7 | eptacog alfa (activated) |
| | 156679-34-4 | lenercept |
| | 124146-64-1 | mobenakin |
| | 0-00-0 | moroctocog alfa |
| | 148641-02-5 | muplestim |
| | 139076-62-3 | octocog alfa |
| 3003 39 00 | 0-00-0 | plusonermin |
| 3003 90 90 | 0-00-0 | fuladectin |
| 3507 90 90 | 143831-71-4 | dornase alfa |
| | 154248-97-2 | imiglucerase |
| | 149394-67-2 | ledismase |
| | 156616-23-8 | monteplase |
| | 159445-63-3 | nateplase |
| | 155773-57-2 | pegorgotein |
| 3911 90 19 | 95522-45-5 | colestilan |
| | 31512-74-0 | polixetonium chloride |
| 3913 90 80 | 39464-87-4 | betasizofiran |
| | 0-00-0 | certoparin sodium |
| | 0-00-0 | minolteparin sodium |

Annex II

Additional pharmaceutical intermediates, ie compounds used for the manufacture of finished pharmaceutical products, to receive duty free treatment.

| CN code | CAS RN | Name |
|------------|-------------|--|
| 2843 30 00 | 12192-57-3 | (alpha-D-glucopyranosylthio)gold |
| 2903 69 90 | 42074-68-0 | 1-chloro-2-(chlorodiphenylmethyl)benzene |
| | 76283-09-5 | alpha,4-dibromo-2-fluorotoluene |
| 2906 29 90 | 104265-58-9 | 2-[(1S,2R)-6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydro-2-naphthyl]ethyl p-toluenesulfonate |
| 2907 29 90 | 700-13-0 | 2,3,5-trimethylhydroquinone |
| 2909 50 90 | 63659-16-5 | 4-[2-(cyclopropylmethoxy)ethyl]phenol |
| 2914 40 90 | 80-75-1 | 11-alpha-hydroxypregn-4-ene-3,20-dione |
| 2914 50 00 | 2107-69-9 | 5,6-dimethoxyindan-1-one |
| | 24916-90-3 | 9-beta,11-beta-epoxy-17,21-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione |
| 2914 70 90 | 83881-08-7 | 21-chloro-9-beta,11-beta-epoxy-17-hydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione |
| 2915 39 90 | 979-02-2 | 20-oxopregna-5,16-dien-3-beta-yl acetate |
| 2915 90 20 | 638-41-5 | pentyl chloroformate |
| 2916 39 00 | 49708-81-8 | trans-4-(p-chlorophenyl)cyclohexanecarboxylic acid |
| 2917 19 90 | 48059-97-8 | (E)-oct-4-ene-1,8-dioic acid |
| | 71170-82-6 | triethyl 3-bromopropane-1,1,1-tricarboxylate |
| 2917 39 80 | 27932-00-9 | indan-5-yl hydrogen phenylmalonate |
| 2918 13 00 | 2743-38-6 | dibenzoyl-L-tartaric acid |
| 2918 17 00 | 4358-88-7 | ethyl DL-mandelate |
| 2918 19 80 | 56188-04-6 | {(1R,3R,5S)-3,5-dihydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]cyclopentyl}acetic acid |
| 2918 29 90 | 167678-46-8 | 3-chloroformyl-o-tolyl acetate |
| 2918 30 00 | 56105-81-8 | (R)-2-(3-benzoylphenyl)propionic acid |
| | 22161-86-0 | (RS)-2-(3-benzoylphenyl)propionic acid |
| | 78834-75-0 | ethyl 7-chloro-2-oxoheptanoate |
| | 1944-63-4 | 3-[(3aS,4S,7aS)-7a-methyl-1,5-dioxooctahydro-1H-inden-4-yl]propionic acid |
| | 39562-17-9 | methyl 2-(3-nitrobenzylidene)-3-oxobutyrate |
| 2918 90 90 | 26159-31-9 | (RS)-2-(6-methoxy-2-naphthyl)propionic acid |
| | 105560-93-8 | methyl (2R,3S)-2,3-epoxy-3-(4-methoxyphenyl)propionate |
| | 40098-26-8 | methyl 7-[(3RS)-3-hydroxy-5-oxocyclopent-1-enyl]heptanoate |
| 2921 19 80 | 4261-68-1 | (2-chloroethyl)diisopropylamine hydrochloride |
| 2921 59 90 | 122-75-8 | N,N'-dibenzylethylenediammonium di(acetate) |
| 2922 19 00 | 126456-43-7 | (1S,2R)-1-aminoindan-2-ol |
| | 68047-07-4 | 4'-[2-(dimethylamino)ethoxy]-2-phenylbutyrophenone |
| 2922 30 00 | 784-38-3 | 2-amino-5-chloro-2'-fluorobenzophenone |
| | 156732-13-7 | (S)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one |
| 2922 49 70 | 37441-29-5 | 5-amino-2,4,6-triiodoisophthaloyl dichloride |
| | 42854-62-6 | benzyl L-alaninate--p-toluenesulfonic acid (1:1) |
| | 39878-87-0 | (-)-alpha-(chloroformyl)benzylammonium chloride |
| | 54527-73-0 | 2-(N-methylbenzylamino)ethyl 3-aminobut-2-enoate |
| | 81677-60-3 | methyl (4-nitrophenyl)-L-alaninate |
| | 949-99-5 | 3-(4-nitrophenyl)-L-alanine |
| 2924 10 00 | 153758-31-7 | (2S)-2-amino-3-hydroxy-N-pentylpropionamide--oxalic acid (1:1) |

ANNEX II

| CN code | CAS RN | Name |
|------------|-------------|--|
| | 138531-07-4 | L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine |
| 2924 29 90 | 40188-45-2 | 3'-acetyl-4'-hydroxybutyranilide |
| 2924 29 90 | 1149-26-4 | N-(benzyloxycarbonyl)-L-valine |
| | 116661-86-0 | (2S,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-4-phenylbutyric acid |
| | 144163-85-9 | tert-butyl [(1S,3S,4S)-4-amino-1-benzyl-3-hydroxy-5-phenylpentyl] carbamate |
| | 149451-80-9 | tert-butyl [(1S,2S)-1-benzyl-2,3-dihydroxypropyl] carbamate |
| | 98737-29-2 | tert-butyl [(S)-alpha-[(S)-oxiranyl]phenethyl] carbamate |
| | 0-00-0 | 2-chloro-N-[2-(2-chlorobenzoyl)-4-nitrophenyl]acetamide |
| | 125971-96-2 | 2-[alpha-(4-fluorobenzoyl)benzyl]-4-methyl-3-oxovaleranalide |
| | 32981-85-4 | methyl (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropionate |
| 2925 19 80 | 151860-15-0 | meso-N-benzyl-3-nitrocyclopropane-1,2-dicarboximide |
| | 97338-03-9 | ethyl (S)-3-(4-aminophenyl)-2-phthalimidopropionate hydrochloride |
| | 94213-26-0 | ethyl (S)-3-{4-[bis(2-chloroethyl)amino]phenyl}-2-phthalimidopropionate hydrochloride |
| 2926 90 80 | 58311-73-2 | (Z)-(2-cyanovinyl)trimethylammonium p-toluenesulfonate |
| | 133481-10-4 | ethyl (1-cyanocyclohexyl)acetate |
| | 123632-23-5 | 4-(2,2,3,3-tetrafluoropropoxy)cinnamionitrile |
| 2928 00 90 | 94213-23-7 | (Z)-[cyano(2,3-dichlorophenyl)methylene]carbazamide |
| 2930 90 16 | 159453-24-4 | N-(benzyloxycarbonyl)-S-phenyl-L-cysteine |
| 2930 90 70 | 159878-02-1 | benzyl (1R,2S)-3-chloro-2-hydroxy-1-(phenylthiomethyl)propylcarbamate |
| | 136511-43-8 | ethyl N-{2-[(acetylthio)methyl]-3-(o-tolyl)-1-oxopropyl}-L-methionate |
| 2932 19 00 | 97148-39-5 | ammonium (Z)-2-methoxyimino-2-(2-furyl)acetate |
| 2932 29 80 | 517-23-7 | alpha-acetyl-gamma-butyrolactone |
| | 6559-91-7 | 4'-demethylepipodophyllotoxin |
| | 39521-49-8 | (3aR,4bS,4R,4aS,5aS)-4-(5,5-dimethyl-1,3-dioxolan-2-yl)hexahydrocyclopropa[3,4]cyclopenta[1,2-b]furan-2(3H)-one |
| | 39746-01-5 | (3aR,4R,5R,6aS)-4-formyl-2-oxohexahydro-2H-cyclopenta[b]furan-5-yl benzoate |
| | 976-70-5 | 3-oxopregn-4-ene-21,17-alpha-carbolactone |
| 2932 99 50 | 32981-86-5 | 10-deacetylbaccatin III |
| 2932 99 70 | 7512-17-6 | 2-acetamido-2-deoxy-beta-D-glucopyranose |
| | 79944-37-9 | trans-6-amino-2,2-dimethyl-1,3-dioxepan-5-ol |
| | 125971-94-0 | tert-butyl [(4R,6R)-6-(cyanomethyl)-2,2-dimethyl-1,3-dioxolan-4-yl]acetate |
| | 467-55-0 | 3-beta-hydroxy-5-alpha-spirostan-12-one |
| | 533-31-3 | 3,4-(methylenedioxy)phenol |

| CN code | CAS RN | Name |
|------------|-------------|---|
| 2933 11 90 | 6150-97-6 | magnesium bis[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methylamino]methanesulfonate |
| 2933 19 90 | 27511-79-1 | 3-aminopyrazole-4-carboxamide hemisulfate |
| 2933 29 90 | 4897-25-0 | 5-chloro-1-methyl-4-nitroimidazole |
| 2933 39 95 | 142057-79-2 | (RS)-2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxyindan-1-one |
| | 120014-07-5 | 2-[(1-benzyl-4-piperidyl)methylene]-5,6-dimethoxyindan-1-one |
| | 6935-27-9 | benzyl(2-pyridyl)amine |
| | 87848-95-1 | 6-bromo-2-pyridyl p-tolyl ketone |
| | 32998-95-1 | N-(tert-butyl)-3-methylpyridine-2-carboxamide |
| 2933 39 95 | 84449-80-9 | 1-[2-(4-carboxyphenoxy)ethyl]piperidinium chloride |
| | 83949-32-0 | 4-carboxy-4-phenylpiperidinium p-toluenesulfonate |
| | 38092-89-6 | 8-chloro-6,11-dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine |
| | 31255-57-9 | 3-[2-(3-chlorophenyl)ethyl]pyridine-2-carbonitrile |
| | 107256-31-5 | 3-[2-(3-chlorophenyl)ethyl]-2-pyridyl 1-methyl-4-piperidyl ketone hydrochloride |
| | 6298-19-7 | 2-chloro-3-pyridylamine |
| | 5424-11-3 | 2,2-diphenyl-4-piperidinovaleronitrile |
| | 108555-25-5 | 1-[2-(4-methoxyphenyl)ethyl]-4-piperidylamine dihydrochloride |
| | 4046-24-6 | 5-(1-methyl-4-piperidyl)-5H-dibenzo[a,d]cyclohepten-5-ol hydrochloride |
| | 139886-04-7 | 1-methyl-1,2,5,6-tetrahydropyridine-3-carbaldehyde (E)-O-methyloxime hydrochloride |
| | 70708-28-0 | 1-(2-pyridyl)-3-(pyrrolidin-1-yl)-1-(p-tolyl)propan-1-ol |
| | 1619-34-7 | quinuclidin-3-ol |
| 2933 40 10 | 105956-96-5 | 7-[3-(tert-butoxycarbonylamino)pyrrolidin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| | 86393-33-1 | 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| | 112811-72-0 | 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| | 98349-25-8 | ethyl 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate |
| 2933 40 90 | 159878-04-3 | benzyl (1S,2S)-3-[(3S,4aS,8aS)-3-tert-butylcarbamoylperhydro-2-isoquinolyl]-2-hydroxy-1-(phenylthiomethyl)propylcarbamate |
| | 159989-64-7 | (3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl]perhydroisoquinoline-3-carboxamide |
| | 159989-65-8 | (3S,4aS,8aS)-N-(tert-butyl)-2-[(2S,3S)-2-hydroxy-3-(3-hydroxy-2-methylbenzamido)-4-(phenylthio)butyl]perhydroisoquinoline-3-carboxamide--methanesulfonic acid (1:1) |
| | 120578-03-2 | 3-[(E)-2-(7-chloro-2-quinolyl)vinyl]benzaldehyde |

ANNEX II

| CN code | CAS RN | Name |
|------------|-------------|---|
| | 1087-69-0 | (9S,13S,14S)-3-methoxymorphinan hydrochloride |
| | 64228-78-0 | pentamethylene bis{3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl]propionate}--oxalic acid (1:2) |
| 2933 59 70 | 75128-73-3 | 2-[(2-acetamido-6-oxo-6,9-dihydro-1H-purin-9-yl)methoxy]ethyl acetate |
| | 3056-33-5 | N-(9-acetyl-6-oxo-6,9-dihydro-1H-purin-2-yl)acetamide |
| | 10310-21-1 | 2-amino-6-chloropurine |
| | 124832-31-1 | 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl N-(benzyloxycarbonyl)-L-valinate |
| | 150378-17-9 | (2R,4S)-2-benzyl-5-[2-(tert-butylcarbonyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-N-[(1S,2R)-2-hydroxyindan-1-yl]valeramide |
| 2933 59 70 | 157810-81-6 | (2R,4S)-2-benzyl-5-[2-(tert-butylcarbonyl)-4-(3-pyridylmethyl)piperazin-1-yl]-4-hydroxy-N-[(1S,2R)-2-hydroxyindan-1-yl]valeramide sulfate |
| | 150323-35-6 | (3S)-1-(tert-butoxycarbonyl)-3-(tert-butylcarbonyl)piperazine |
| | 41202-32-8 | 1-(2-chlorophenyl)piperazine hydrochloride |
| | 13078-15-4 | 1-(3-chlorophenyl)piperazine hydrochloride |
| | 71-30-7 | cytosine |
| | 149062-75-9 | 1,3-dichloro-6,7,8,9,10,12-hexahydroazepino[2,1-b]quinazoline hydrochloride |
| | 41202-77-1 | 1-(2,3-dichlorophenyl)piperazine hydrochloride |
| | 56177-80-1 | 2-ethoxy-5-fluoropyrimidin-4(1H)-one |
| | 112733-45-6 | ethyl (7-chloro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-1-yl)acetate |
| | 59703-00-3 | 4-ethyl-2,3-dioxopiperazine-1-carbonyl chloride |
| | 64090-19-3 | 1-(4-fluorophenyl)piperazine dihydrochloride |
| | 147539-21-7 | isopropyl [2-(piperazin-1-yl)-3-pyridyl]amine |
| | 35386-24-4 | 1-(2-methoxyphenyl)piperazine |
| | 5464-78-8 | 1-(2-methoxyphenyl)piperazine hydrochloride |
| | 145012-50-6 | (7RS,9aRS)-perhydropyrido[1,2-a]pyrazin-7-ylmethanol |
| | 2210-93-7 | 1-phenylpiperazinium chloride |
| | 111641-17-9 | 4-(piperazin-1-yl)-2,6-bis(pyrrolidin-1-yl)pyrimidine |
| | 68-94-0 | purin-6(1H)-one |
| | 70849-60-4 | 1-(o-tolyl)piperazine hydrochloride |
| 2933 69 80 | 58909-39-0 | tetrahydro-2-methyl-3-thioxo-1,2,4-triazine-5,6-dione |
| 2933 79 00 | 135297-22-2 | (3S,4R)-3-[(R)-1-(tert-butyl)dimethylsilyloxy]ethyl]-4-[(1R,3S)-3-methoxy-2-oxocyclohexyl]azetid-2-one |
| | 141646-08-4 | 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl 1-(1-hydroxyethyl)-5-methoxy-2-oxo-1,2,5,6,7,8,8a,8b-octahydroazeto[2,1-a]isoindole-4-carboxylate |
| | 132127-34-5 | (3R,4S)-3-hydroxy-4-phenylazetid-2-one |
| | 75363-99-4 | p-nitrobenzyl (2R,5R,6S)-6-[(R)-1-hydroxyethyl]-3,7-dioxo-1- |

ANNEX II

| CN code | CAS RN | Name |
|------------|-------------|--|
| | 141316-45-2 | azabicyclo[3.2.0]heptane-2-carboxylate potassium 1-(1-hydroxyethyl)-5-methoxy-2-oxo-1,2,5,6,7,8,8a,8b-octahydroazeto[2,1-a]isoindole-4-carboxylate |
| 2933 90 60 | 59467-64-0 | [7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-yl]methylamine |
| | 59469-29-3 | [7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-ylmethyl]ammonium bis(maleate) |
| | 59467-69-5 | 8-chloro-6-(2-fluorophenyl)-1-methyl-3a,4-dihydro-3H-imidazo[1,5-a][1,4]benzodiazepine |
| | 59469-63-5 | 7-chloro-5-(2-fluorophenyl)-3-methyl-2-(nitromethylene)-2,3-dihydro-1H-1,4-benzodiazepine 4-oxide |
| | 59467-63-9 | 7-chloro-5-(2-fluorophenyl)-2-(nitromethylene)-2,3-dihydro-1H-1,4-benzodiazepine |
| 2933 90 95 | 130404-91-0 | N-[(R)-2-((R)-2-((2-adamantylloxycarbonyl)amino)-3-(1H-indol-3-yl)-2-methyl-1-oxopropyl)amino)-1-phenylethyl]succinamic acid--1-deoxy-1-methylamino-D-glucitol (1:1) |
| | 122536-48-5 | 3-[(S)-3-(L-alanyl)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid hydrochloride |
| | 122536-91-8 | 7-[(S)-3-[(S)-2-(tert-butoxycarbonylamino)-1-oxopropylamino]pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid |
| | 134575-17-0 | tert-butyl meso-3-azabicyclo[3.1.0]hex-6-ylcarbamate |
| | 122536-66-7 | tert-butyl [(S)-1-methyl-2-oxo-2-[(S)-4-pyrrolidin-3-ylamino]ethyl]carbamate |
| | 140629-77-2 | tert-butyl [(RS)-pyrrolidin-3-yl]carbamate |
| | 100361-18-0 | 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid |
| | 38150-27-5 | 5-chloro-2-[3-(hydroxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]benzophenone |
| | 36916-19-5 | 5-chloro-2-(3-methyl-4H-1,2,4-triazol-4-yl)benzophenone |
| | 54196-62-2 | 2',5-dichloro-2-[3-(hydroxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]benzophenone |
| | 54196-61-1 | 2',5-dichloro-2-(3-methyl-4H-1,2,4-triazol-4-yl)benzophenone |
| | 141113-28-2 | (E)-(+)-2-(2,4-difluorophenyl)-1-(3-[4-(2,2,3,3-tetrafluoropropoxy)styryl]-1H-1,2,4-triazol-1-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol |
| | 141113-41-9 | (R)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)propane-1,2-diol |
| | 144034-80-0 | dimethyl{2-[5-(1H-1,2,4-triazol-1-ylmethyl)indol-3-yl]ethyl}amine |
| | 122665-86-5 | ethyl [3-(cyanomethyl)-4-oxo-3,4-dihydrophthalazin-1-yl]acetate |
| | 41340-36-7 | 2-(7-ethyl-1H-indol-3-yl)ethanol |
| | 95885-13-5 | 5-ethyl-4-(2-phenoxyethyl)-4H-1,2,4-triazol- |

ANNEX II

| CN code | CAS RN | Name |
|------------|-------------|---|
| | | 3 (2H) -one |
| | 96107-94-7 | ethyl 1H-tetrazole-5-carboxylate, sodium salt |
| | 96034-57-0 | trans-4-hydroxy-1-(4-nitrobenzyloxycarbonyl)-L-proline |
| | 160194-26-3 | 2-iodo-4-(1H-1,2,4-triazol-1-ylmethyl)aniline |
| | 66635-71-0 | isopropyl 2,3-dihydro-1H-pyrrolizine-1-carboxylate |
| | 4928-88-5 | methyl 1H-1,2,4-triazole-3-carboxylate |
| | 0-00-0 | 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid sulfate |
| | 112193-77-8 | 1,4,7,10-tetraazoniacyclododecane bis(sulfate) |
| | 3641-08-5 | 1H-1,2,4-triazole-3-carboxamide |
| | 4928-87-4 | 1H-1,2,4-triazole-3-carboxylic acid |
| | 6969-71-7 | 1,2,4-triazolo[4,3-a]pyridin-3(2H)-one |
| 2934 10 00 | 171485-87-3 | 2-[4-(2-amino-4-oxo-4,5-dihydrothiazol-5-ylmethyl)phenoxyethyl]-2,5,7,8-tetramethylchroman-6-yl acetate |
| | 65872-41-5 | (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid |
| | 64486-18-6 | (Z)-2-[2-(chloroacetamido)thiazol-4-yl]-2-(methoxyimino)acetic acid |
| | 76823-93-3 | 1-(4-[(2-cyanoethyl)thiomethyl]thiazol-2-yl)guanidine |
| 2934 10 00 | 139340-56-0 | {5-[(Z)-3,5-di(tert-butyl)-4-hydroxybenzylidene]-4-oxo-4,5-dihydrothiazol-2-yl}ammonium methanesulfonate |
| | 64485-88-7 | ethyl (Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetate |
| | 66339-00-2 | ethyl 2-(hydroxyimino)-2-[2-(tritylamino)thiazol-4-yl]acetate hydrochloride |
| | 88046-01-9 | 2-guanidinothiazol-4-ylmethyl carbamimidothioate dihydrochloride |
| | 154212-61-0 | N-[2-isopropylthiazol-4-ylmethyl(methyl)carbamoyl]-L-valine |
| | 66215-71-2 | (Z)-2-methoxyimino-2-[2-(tritylamino)thiazol-4-yl]acetic acid |
| | 154212-59-6 | 4-nitrophenyl thiazol-5-ylmethyl carbonate hydrochloride |
| | 38585-74-9 | thiazol-5-ylmethanol |
| | 155213-67-5 | thiazol-5-ylmethyl (1S,2S,4S)-1-benzyl-2-hydroxy-4-[(2S)-2-[3-(2-isopropylthiazol-4-ylmethyl)-3-methylureido]-3-methylbutylamido]-5-phenylpentylcarbamate |
| 2934 20 50 | 80756-85-0 | S-(benzothiazol-2-yl) (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminothioacetate |
| 2934 20 90 | 87691-88-1 | 1-(1,2-benzisothiazol-3-yl)piperazine hydrochloride |
| 2934 90 50 | 111974-69-7 | 2-[2-[4-(dibenzo[b,f][1,4]thiazepin-10-yl)piperazin-1-yl]ethoxy]ethanol |
| | 42399-49-5 | (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-3,3-dihydro-1,5-benzothiazepin-4(5H)-one |
| 2934 90 60 | 115787-67-2 | 2-(2-amino-5-nitro-6-oxo-1,6-dihydropyrimidin-4-yl)-3-(3-thienyl)propionitrile |
| | 117829-20-6 | 2-amino-7-phenyl-1,7-dihydro-4H-pyrrole[2,3-d]pyrimidin-4-one hydrochloride |

ANNEX II

| CN code | CAS RN | Name |
|------------|-------------|---|
| | 112887-68-0 | N-{5-[(1,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)methylamino]-2-thenoyl}-L-glutamic acid |
| | 161005-84-1 | (S)-N,N-dimethyl-[3-(2-thienyl)-3-(1-naphthyloxy)propyl]amine--phosphoric acid (1:1) |
| | 104795-66-6 | 3-isopropoxy-5-methoxy-N-(1H-tetrazol-5-yl)benzo[b]thiophene-2-carboxamide |
| | 104795-67-7 | 3-isopropoxy-5-methoxy-N-(1H-tetrazol-5-yl)benzo[b]thiophene-2-carboxamide--1H-imidazole (1:1) |
| | 104795-68-8 | 3-isopropoxy-5-methoxy-N-(1H-tetrazol-5-yl)benzo[b]thiophene-2-carboxamide, sodium salt |
| | 63675-74-1 | 6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene |
| | 138564-59-7 | 5-methyl-2-(2-nitroanilino)thiophene-3-carbonitrile |
| 2934 90 70 | 25229-97-4 | 2-cyano-3-morpholinoacrylamide |
| 2934 90 80 | 119221-49-7 | 5-[(2-aminoethyl)amino]-2-(2-diethylaminoethyl)-2H-[1]benzothiopyrano[4,3,2-cd]indazol-8-ol (4S,6S)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-4-ol 7,7-dioxide |
| | 147086-81-5 | adenosine |
| 2934 90 98 | 58-61-7 | (8)-4-(4-aminobenzyl)oxazolidin-2-one |
| | 152305-23-2 | 7-amino-3-[1-(sulfomethyl)-1H-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acid, sodium salt |
| | 71420-85-4 | 3'-azido-3'-deoxy-5'-O-tritylthymidine |
| 2934 90 98 | 51762-51-7 | benzhydryl 3-hydroxy-7-(phenylacetamido)cepham-4-carboxylate |
| | 110314-42-6 | 5-[(benzofuran-2-ylcarbonyl)amino]indole-2-carboxylic acid |
| | 131986-28-2 | 3-(4-chloro-1,2,5-thiadiazol-3-yl)pyridine |
| | 107452-89-1 | omega-conotoxin M VIIA |
| | 126429-09-2 | 2-(dichloromethyl)-4,5-dihydro-5-(4-mesylphenyl)oxazol-4-ylmethanol |
| | 126813-11-4 | (4R,5R)-2-(dichloromethyl)-4,5-dihydro-5-(4-mesylphenyl)oxazol-4-ylmethanol |
| | 4097-22-7 | 2',3'-dideoxyadenosine |
| | 139264-17-8 | (S)-4-{[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl}oxazolidin-2-one |
| | 110351-94-5 | (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione |
| | 140841-32-3 | 6-[3-fluoro-5-(4-methoxytetrahydropyran-4-yl)phenoxyethyl]-1-methyl-2-quinolone |
| | 94732-98-6 | 1-(1-{3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl}-4-piperidyl)-2,3-dihydro-1H-benzimidazole-2-thione |
| | 125995-03-1 | (4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-4-hydroxytetrahydro-2H-pyran-2-one |
| | 131988-19-7 | 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1-methylpyridinium iodide |
| | 147027-10-9 | (1R,2S,5R)-menthyl (2R,5S)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-1,3-oxathiolane-2- |

ANNEX II

| CW code | CAS RN | Name |
|------------|-------------|---|
| | | carboxylate |
| | 147126-62-3 | (1R,2S,5R)-menthyl (2R,5R)-5-hydroxy-1,3-oxathiolane-2-carboxylate |
| | 104218-44-2 | 3'-O-mesyl-5'-O-tritylthymidine |
| | 27255-72-7 | 3-methyl-7-(phenylacetamido)-3-cephem-4-carboxylic acid |
| | 0-00-0 | (1R,2S,3S,6R)-[(S)-1-phenylethyl]-3,6-epoxytetrahydrophthalimide |
| | 32231-06-4 | 1-piperonylpiperazine |
| | 55612-11-8 | 5'-O-tritylthymidine |
| 2935 00 90 | 151140-66-8 | (4-amino-3-iodophenyl)-N-methylmethanesulfonamide |
| | 112101-81-2 | 5-[(R)-(2-aminopropyl)]-2-methoxybenzenesulfonamide |
| | 120298-38-6 | N-(5,6-dihydro-6-methyl-2-sulfamoyl-4H-thieno[2,3-b]thiopyran-4-yl)acetamide 7,7-dioxide |
| | 150975-95-4 | 5-methanesulfonamidoindole-2-carboxylic acid |
| | 84522-34-9 | sodium 4-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulfonamide |
| 2939 10 00 | 66820-84-6 | (RS)-tetrahydropapaverine hydrochloride |
| 2940 00 90 | 13035-61-5 | 1,2,3,5-tetraacetyl-beta-D-ribofuranose |
| 3824 90 64 | 330-95-0 | 1,3-bis(4-nitrophenyl)urea--4,6-dimethylpyrimidin-2-ol (1:1) |
| | 104832-01-1 | (R)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinoline--dibenzoyl-L-tartaric acid (1:1) |
| | 0-00-0 | Intermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human granulocyte-macrophage colony-stimulating factor; for use in the manufacture of medicaments of HS No. 3002 |
| 3824 90 64 | 0-00-0 | Intermediate concentrate obtained from a genetically-modified Escherichia coli fermentation medium, containing human interferon alpha-2b; for use in the manufacture of medicaments of HS No. 3002 |
| | 0-00-0 | Intermediate concentrates obtained from a Micromonospora inyoensis fermentation medium used for the manufacture of the antibiotics sisomicin (INN) and netilmicin (INN) |
| | 0-00-0 | Intermediate concentrates obtained from a Micromonospora purpurea fermentation medium used for the manufacture of the antibiotics gentamicin sulfate (INN) and isepamicin (INN) |
| 3824 90 95 | 0-00-0 | ethyl 7-chloro-2-oxoheptanoate, in the form of a solution in toluene |
| 3911 90 | 162430-94-6 | 1,6-hexanediamine, polymer with 1,10-dibromodecane |
| 3913 90 80 | 83513-48-8 | danaparoid sodium |

Annex III

Additions to the list of prefixes and suffixes which, in combination with the INNs, describe salts, esters or hydrates of INNs.

ACETURATE
N-ACETYLGLYCINATE
ACISTRATE
ACOXIL
AMSONATE
BENZATHINE
BEZOMIL
BUCICLATE
BUNAPSILATE
BUTEPRATE
BUTYL ESTER
CARBESILATE
p-CHLOROBENZENESULFONATE
p-CHLOROBENZENESULPHONATE
CICLOTATE
CIPIONATE
CLOSILATE
CLOSYLATE
CROBEFATE
CROMACATE
CROMESILATE
CYCLOPENTANEPROPIONATE
CYCLOTATE
CYPIONATE
DAPROPATE
DEANIL
DECIL
DIBUDINATE
DIBUNATE
DIETHANOLAMINE
DIGOLIL
N,N-DIMETHYL-beta-ALANINE
DIOLAMINE
DOCOSIL
DOFOSFATE
EDAMINE
EDISYLATE
EPOLAMINE
ERBUMINE
ETABONATE
ETHANOLAMINE
ETHYLENEDIAMINE
FARNESIL
FENDIZOATE
FOSTEDATE
HIBENZATE
HYBENZATE
HYCLATE
o-(4-HYDROXYBENZOYL)BENZOATE
ISOCAPROATE
LAURIL
LAURILSULFATE
LAURILSULPHATE
LAURYL
LAURYSULFATE
LAURYSULPHATE
MEGALLATE
METEMBONATE
4-METHYLBICYCLO[2.2.2]OCT-2-ENE-1-CARBOXYLATE
MOFETIL
OCTIL
OLAMINE
OXOGLURATE
PENDETIDE

PIVOXETIL
PROXETIL
1-PYRROLIDINEETHANOL
SODIUM LAURIL SULFATE
SODIUM LAURIL SULPHATE
SODIUM LAURYL SULFATE
SODIUM LAURYL SULPHATE
STEAGLATE
TENOATE
TEPROSILATE
TETRADECYL HYDROGEN PHOSPHATE
TOFESILATE
TRICLOFENATE
TRIETHANOLAMINE
TRIFLUTATE
TROLAMINE
TROMETAMOL
TROMETHAMINE
Troxundate
XINAFOATE

Annex IV

INNs which shall no longer benefit from duty free treatment

| CN code | CAS RN | Name |
|------------|------------|---------------------|
| 2903 22 00 | 79-01-6 | trichloroethylene |
| 2903 30 10 | 811-97-2 | norflurane |
| 2903 51 10 | 58-89-9 | lindane |
| 2906 21 00 | 100-51-6 | benzyl alcohol |
| 2915 29 00 | 82279-57-0 | zinc acetate, basic |
| 2922 41 00 | 56-87-1 | lysine |
| 2922 42 90 | 56-86-0 | glutamic acid |
| 2922 49 10 | 56-40-6 | glycine |
| 2922 50 00 | 72-19-5 | threonine |
| 2923 10 10 | 67-48-1 | choline chloride |
| 2928 00 90 | 79-17-4 | pimagedine |
| 2930 90 20 | 111-48-8 | thiodiglycol |
| 2933 90 95 | 73-22-3 | tryptophan |
| 3102 70 10 | 156-62-7 | calcium carbimide |
| 3904 61 10 | 9002-84-0 | politef |
| 3906 90 90 | 54182-57-9 | carbomer |
| 3907 20 | 0-00-0 | macrogol ester |
| 3907 20 12 | 25322-68-3 | macrogol |
| 3907 20 21 | 25301-02-4 | tyloxapol |
| 3907 60 10 | 25038-59-9 | pegoterate |
| 3908 10 00 | 25038-54-4 | policapram |
| 3910 00 00 | 9006-65-9 | dimeticone |
| 3912 20 11 | 9004-70-0 | pyroxylin |
| 3912 31 00 | 9000-11-7 | carmellose |
| 3912 39 80 | 8063-82-9 | hypromellose |

ISSN 0254-1475

COM(96) 563 final

DOCUMENTS

EN

02 05 09 15

Catalogue number : CB-CO-96-562-EN-C

ISBN 92-78-10884-7

Office for Official Publications of the European Communities

L-2985 Luxembourg